GlassScriptPhysician profile
Thomas John Muelleman
NPI 1972846491
$2,674.96
in general payments reported to CMS, 2019-2025
23 companies · $956 in 2025
The $956 reported for 2025 was more than what a typical Otology & Neurotology provider received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.43 · 2020: $130 · 2021: $176 · 2022: $466 · 2023: $483 · 2024: $411 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.30 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $600.00 | 2025 | |
| Genzyme Corporation | $505.40 | 2021-2025 | |
| Advanced Bionics, LLC | $278.61 | 2019-2024 | Hires Ultra Ci Hifocus Ms Electrode |
| Regeneron Healthcare Solutions, INC. | $267.90 | 2021-2025 | Dupixent |
| Cochlear Americas | $142.13 | 2023 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Stryker Corporation | $124.26 | 2022-2024 | Scopis Ent, Xpress Ent Dilation System |
| Acclarent, INC | $116.47 | 2020-2024 | Trudi Nav Cable, Acclarent Aera |
| Smith+Nephew, INC. | $107.96 | 2025 | Tula, Halo |
| Optinose US, INC. | $96.33 | 2020-2024 | |
| Baudax Bio INC. | $59.95 | 2022 | |
| Glaxosmithkline, LLC. | $57.11 | 2022-2024 | Nucala |
| Olympus America INC. | $47.55 | 2020-2022 | |
| Innovation Technologies INC | $37.02 | 2023 | Irrisept |
| Merck Sharp & Dohme LLC | $31.22 | 2021-2025 | Keytruda |
| Ascendis Pharma Endocrinology INC | $29.19 | 2025 | Yorvipath |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $27.57 | 2021 | |
| Alk-Abello, INC | $26.84 | 2021 | |
| Sanofi-Aventis U.S. LLC | $25.05 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $23.96 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.41 | 2025 | Voquezna |
| Integra Lifesciences Corporation | $18.48 | 2023 | Tenoglide |
| Greer Laboratories, INC. | $18.20 | 2023 | Oralair |
| Genentech USA, INC. | $13.35 | 2023 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Muelleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.